Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
- New preclinical data show potential of ImmTAV platform to facilitate specific and rapid elimination of Hepatitis B‐infected cells with the goal of achieving functional cure
- Lead bispecific candidate, IMC-I109V, to progress into first‐in‐human clinical trials for the treatment of chronic Hepatitis B
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 August 2020) Immunocore (or the “Company”), a pioneering, clinical‐stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announces publication of a novel therapeutic approach with the potential to provide a functional cure for chronic hepatitis B, in leading peer reviewed journal Hepatology.